VZV gI Antibody (8C4): sc-56997

VZV gI Antibody (8C4) is a mouse monoclonal IgG1 antibody that detects the VZV gI protein of Varicella Zoster Virus origin by western blotting (WB) and immunofluorescence (IF). Anti-VZV gI antibody (8C4) is available as a non-conjugated format. The Varicella Zoster Virus (VZV) is notorious for causing two significant diseases: childhood chickenpox (varicella) and shingles (zoster). Once the initial infection occurs, VZV can become dormant in sensory ganglia, potentially reactivating years later to cause shingles. VZV gI protein plays a crucial role in the virus′s life cycle, particularly in the trans-Golgi network (TGN), where VZV gI protein is essential for viral envelopment and efficient membrane fusion during replication. The structure of VZV gI protein is particularly important, as the C-terminal domain is necessary for the segregation of viral and cellular proteins within the enveloping TGN cisternae, while the amino-terminus is critical for the formation of the glycoprotein E (gE)-gI complex, which is vital for viral infection of host cells. Glycoprotein E, a major component of the virion envelope, is activated by immediate-early proteins IE4 and IE62, highlighting the intricate regulatory mechanisms involved in VZV pathogenesis. VZV gI protein is not only pivotal for viral replication in Vero cells but also for overall efficiency in nonhuman cells and proper processing of gE, making VZV gI protein a key target for research and therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VZV gI Antibody (8C4) References:

1. Transcription factor Sp1 is involved in the regulation of varicella-zoster virus glycoprotein E.  |  Rahaus, M. and Wolff, MH. 2000. Virus Res. 69: 69-81. PMID: 10989187
2. Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument.  |  Wang, ZH., et al. 2001. J Virol. 75: 323-40. PMID: 11119602
3. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates.  |  Kleinschmidt-DeMasters, BK. and Gilden, DH. 2001. Arch Pathol Lab Med. 125: 770-80. PMID: 11371229
4. Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I.  |  Kimura, H., et al. 1997. Virology. 233: 382-91. PMID: 9217061
5. Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.  |  Cohen, JI. and Nguyen, H. 1997. J Virol. 71: 6913-20. PMID: 9261418
6. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.  |  Mallory, S., et al. 1997. J Virol. 71: 8279-88. PMID: 9343180

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VZV gI Antibody (8C4) has 0 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VZV gI Antibody (8C4) Specifications

Alternate Product Name: VZV gI

Product Clone Name: 8C4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: VZV gI

Epitope Species: Varicella Zoster virus

Product Reactivity/Detection: glycoprotein I

Species Reactivity/Detection: Varicella Zoster Virus

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF

Vialing Information: Each vial contains 50 µg IgG₁ in 0.5 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for VZV gI Antibody (8C4): N/A